Company Overview

For personal use only Leadership Team Joel Latham Managing Director and CEO Joel Latham is the CEO and Managing Director of Incannex Healthcare and is responsible for the Company's commercial operations, strategic decision-making, and oversight of all clinical development assets. Joel has over 15 years commercial management and executive experience, working for a range multi-national publicly traded companies. Lekhram Changoer, MSc Chief Technical Officer Mr. Changoer is responsible for the Company's R&D, clinical and product development, commercial operations, quality assurance, Sales and Marketing of technical, consumer healthcare and pharmaceutical products. He has co-developed several cannabinoid patents. Incannex Troy Valentine Chairman of the Board of Directors Troy Valentine has been Chairman of the Board of Directors since December 2017. Troy is a finance professional with extensive managerial and Board experience. Dr Mark Bleackley Chief Scientific Officer Dr Bleackley has a PhD in Genetics from the University of British Columbia with post- doctoral training at La Trobe University and Australian biotechnology company Hexima Ltd. He oversees all research and development activities at Incannex, from proof-of-concept to commercialization. Peter Widdows Non-Executive Director Peter Widdows is the former CEO covering a large part of Asia and Australasia for the H. J. Heinz Co. He is also the Non-Executive Chairman of Sunny Queen Australia, Australia's largest egg and egg based meal producer and a Non-Executive Director of Youi - a general insurance company. Peter has extensive experience as a senior executive/CEO in many geographies including the UK, USA, Asia and Australasia. He is also a Fellow Chartered Accountant. Madhukar Bhalla Company Secretary Madhukar "Madhu" is an experienced company secretary who has previously worked with multiple ASX-listed companies and is proficient in corporate governance, company administration, financial management and corporate law. George Anastassov, MD DDS, MBA Non-Executive Director Dr. Anastassov is one of the developers of the first-in-the-world cannabinoid-containing chewing gum-based delivery system among a number of other systems and formulations. Previously, he was CEO and Co-founder of AXIM Biotechnologies, driving market capitalization to over USD $1.2 billion. Rosemarie Walsh Vice President, Clinical Operations Rosemarie Walsh has a degree in Applied Biology from RMIT University and over 20 year's experience in clinical trials including concept/ design, start-up, conduct and close out, having worked for global and local contract research organizations and global pharma. As VP clinical operations, Rosemarie oversees all aspects of Incannex's clinical trials. Investor Presentation

View entire presentation